News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an "overweight" rating on the stock.

Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]

Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

11/7/2024

06:30 am

mrna

-12.4%

BEAT

8/1/2024

06:30 am

mrna

-18.1%

BEAT

5/2/2024

06:30 am

mrna

11.9%

BEAT

2/22/2024

06:30 am

mrna

14.3%

BEAT

Needham & Company LLC

Form 4 Moderna, Inc. For: Nov 08 Filed by: Hoge Stephen

Form 144 Moderna, Inc. Filed by: Hoge Stephen

Form 10-Q Moderna, Inc. For: Sep 30

Form 8-K Moderna, Inc. For: Nov 07

Form 4 Moderna, Inc. For: Oct 04 Filed by: Mock James M

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}